Digest Network Come funziona
Network
/
Società
Me
Non verificato

Meitheal Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

9 comunicati stampa

Guarda tutti i comunicati
04/11/2025
Industria
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Meitheal Pharmaceuticals Receives Approval from the US Food and Drug Administration for CONTEPO™ (fosfomycin) for injection in Patients ≥ 18 Years Having Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP)
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
20/10/2025
Eventi
Industria
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Meitheal Pharmaceuticals to Present New Data in Infectious Disease Portfolio at IDWeek 2025
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
31/07/2025
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
Industria
Meitheal Pharmaceuticals Announces Appointment of Dr. Keith Robinson as Chief Medical Officer and Expansion of Medical Affairs Operation
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/05/2025
Biotecnologia
Salute
Farmaceutica
Attrezzature medico-sanitarie
Oncologia
Mercato del lavoro
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/04/2025
Industria
Scienza
Sanità
Farmaceutica
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
Meitheal Pharmaceuticals Announces Approval and Launch of Liraglutide Injection in the United States
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/12/2024
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Mercato del lavoro
Industria
Meitheal Pharmaceuticals Grows Specialty Biopharmaceuticals Portfolio with Exclusive Commercial Licensing Agreement for XENLETA® (lefamulin acetate)
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
31/10/2024
Mercato del lavoro
Biotecnologia
Sanità
Farmaceutica
Salute
Meitheal Pharmaceuticals Secures Exclusive Commercial Licensing Agreement for Three Biosimilars in the U.S.
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
18/07/2024
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Mercato azionario
Industria
Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/06/2024
Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for YUSIMRY®, a Biosimilar of Humira®
Fonte
Meitheal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0